{"success":true,"data":{"pressRelease":{"id":"146793","rtpr_id":"nPNAq8j2Ka-20260917","ticker":"VIRB","exchange":"Euronext Paris","all_tickers":["VIRB"],"title":"A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%","author":"PR Newswire","published_at":"2026-09-17T16:33:42.095Z","article_body":"A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth\nof 7.4%\nPR Newswire\n\nPARIS, Sept. 18, 2026\n\nPARIS, Sept. 18, 2026 /PRNewswire/ -- \n\n\n* H1 2026 delivered a robust revenue growth of +7.4% and an adjusted EBIT\nmargin of 18.8% at CERS:\n○  Revenue growth is coming from both segments : companion animal +10.0%\nand farm animal +6.7% with a strong contribution from our Supercharge\nplatforms (excl. Thyronorm) which increased by around +12% at CERS\n○  Solid volume/mix effect of ~+5.4%, completed by price increase of ~+2%\n○  Operating margin increased by 0.5ppt compared to H1 2025 driven by a\nfavorable mix effect on the gross margin partially offset by higher operating\nexpenses due to H1/H2 phasing effects.\n* Consolidated net income increased by +5.9% to €87.1 million\n* Net Debt as of June 2026 up to €196 million compared to €173m as of\nDecember 2025 mainly driven by usual working capital requirement seasonality\n2026 guidance confirmed at the upper end of the range: the strong performance\nachieved in the first half of the year positions us to target the upper end of\nour initial revenue growth range (5.5% to 7.5% at CERS) and an adjusted\nrecurring operating income margin of around 17% at CERS\n\nPaul Martingell, Chief Executive Officer statement\n\n\"Virbac delivered a strong first half, marked by +7.4% organic growth and an\n18.8% operating margin, demonstrating our teams' ability to turn our\ncommitment to animal health into tangible value. This performance reflects the\nscaling power of our 'Supercharge' platforms and the seamless integration of\nThyronorm. Guided by our 'Growing Together' 2030 strategy, we are fully on\ntrack to achieve our full-year guidance.\"\n\nTo be noted: EBIT Adjusted (before amortizations) corresponds to \"recurring\noperating income before amortization of assets arising from acquisitions\".\n\nMedia Contact: contact@virbac.com\n\n \n\n\n\nSOURCE Virbac\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1988977/VBD_01.jpg?id=OA2950466\nhttps://mmx.prnewswire.com/media/MS1886376/logo-virbac-2.jpg?id=OA2950467\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPNAq8j2Ka-20260917","title":"A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%","author":"PR Newswire","ticker":"VIRB","created":"2026-09-17T16:33:42.095Z","tickers":["VIRB"],"exchange":"Euronext Paris","article_body":"A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth\nof 7.4%\nPR Newswire\n\nPARIS, Sept. 18, 2026\n\nPARIS, Sept. 18, 2026 /PRNewswire/ -- \n\n\n* H1 2026 delivered a robust revenue growth of +7.4% and an adjusted EBIT\nmargin of 18.8% at CERS:\n○  Revenue growth is coming from both segments : companion animal +10.0%\nand farm animal +6.7% with a strong contribution from our Supercharge\nplatforms (excl. Thyronorm) which increased by around +12% at CERS\n○  Solid volume/mix effect of ~+5.4%, completed by price increase of ~+2%\n○  Operating margin increased by 0.5ppt compared to H1 2025 driven by a\nfavorable mix effect on the gross margin partially offset by higher operating\nexpenses due to H1/H2 phasing effects.\n* Consolidated net income increased by +5.9% to €87.1 million\n* Net Debt as of June 2026 up to €196 million compared to €173m as of\nDecember 2025 mainly driven by usual working capital requirement seasonality\n2026 guidance confirmed at the upper end of the range: the strong performance\nachieved in the first half of the year positions us to target the upper end of\nour initial revenue growth range (5.5% to 7.5% at CERS) and an adjusted\nrecurring operating income margin of around 17% at CERS\n\nPaul Martingell, Chief Executive Officer statement\n\n\"Virbac delivered a strong first half, marked by +7.4% organic growth and an\n18.8% operating margin, demonstrating our teams' ability to turn our\ncommitment to animal health into tangible value. This performance reflects the\nscaling power of our 'Supercharge' platforms and the seamless integration of\nThyronorm. Guided by our 'Growing Together' 2030 strategy, we are fully on\ntrack to achieve our full-year guidance.\"\n\nTo be noted: EBIT Adjusted (before amortizations) corresponds to \"recurring\noperating income before amortization of assets arising from acquisitions\".\n\nMedia Contact: contact@virbac.com\n\n \n\n\n\nSOURCE Virbac\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1988977/VBD_01.jpg?id=OA2950466\nhttps://mmx.prnewswire.com/media/MS1886376/logo-virbac-2.jpg?id=OA2950467\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-17T16:33:42.154353702Z","server_sent_at_ms":1789662822154},"received_at":"2026-09-17T16:33:42.207Z","source_url":null},"analysis":{"id":"135625","press_release_id":"146793","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["FY margin guidance of ~17% implies a softer H2 versus H1's 18.8% adjusted EBIT margin","Net debt increased to €196 million from €173 million at December 2025 (company attributes to working-capital seasonality)","No absolute revenue figure disclosed in the release, only growth rates"],"eventType":"earnings","narrative":"Virbac delivered H1 2026 organic revenue growth of +7.4% with an adjusted EBIT margin of 18.8%, up 0.5ppt versus H1 2025.\n\nGrowth was broad-based: companion animal rose +10.0% and farm animal +6.7% at CERS, with Supercharge platforms up around +12% and a ~+5.4% volume/mix contribution plus ~+2% price.\n\nConsolidated net income increased +5.9% to €87.1 million, while net debt rose to €196 million from €173 million at year-end 2025, attributed mainly to normal working-capital seasonality.\n\nManagement confirmed 2026 guidance at the upper end of the initial range, targeting 5.5%-7.5% revenue growth at CERS and an adjusted recurring operating income margin of around 17%.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Animal-health demand stays resilient -- Virbac tracking to the upper end of 2026 guidance with margin expansion and double-digit Supercharge platform growth."},"keyFigures":{"guidance":"2026 revenue growth at the upper end of the 5.5%-7.5% CERS range; adjusted recurring operating income margin around 17% at CERS","revenueYoy":"+7.4% organic growth at CERS","customDimensions":{"net_debt":"€196 million (June 2026)","net_income":"€87.1 million","price_effect":"~+2%","net_debt_dec_2025":"€173 million","net_income_growth":"+5.9%","volume_mix_effect":"~+5.4%","farm_animal_growth":"+6.7% at CERS","adjusted_ebit_margin":"18.8%","companion_animal_growth":"+10.0% at CERS","operating_margin_change":"+0.5ppt vs H1 2025","supercharge_platform_growth":"+12% at CERS (excl. Thyronorm)"}},"quotedText":"Virbac delivered a strong first half, marked by +7.4% organic growth and an 18.8% operating margin, demonstrating our teams' ability to turn our commitment to animal health into tangible value.","namedEntities":{"people":[{"name":"Paul Martingell","role":"Chief Executive Officer"}],"products":["Supercharge platforms","Thyronorm"],"companies":[{"name":"Virbac","ticker":"VIRB","relationship":"filer"}],"dollarAmounts":[{"amount":"€87.1 million","context":"H1 2026 consolidated net income"},{"amount":"€196 million","context":"net debt as of June 2026"},{"amount":"€173m","context":"net debt as of December 2025"}]},"materialImpact":{"score":4,"reasoning":"H1 2026 results show 7.4% organic revenue growth, an 18.8% adjusted EBIT margin (+0.5ppt YoY), net income up 5.9% to €87.1M, and full-year guidance confirmed at the upper end of the initial range. Not a >10% surprise (no consensus cited), but a strong print with a de facto guidance upgrade toward the top of the range."},"tickerRelevance":{"others":[],"primary":"VIRB"},"globalImportance":42,"audienceRelevance":35,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"tickerTier":"large European animal-health issuer (Euronext Paris)","eventGravity":"H1 earnings with growth and margin expansion plus upper-end guidance confirmation","sectorWeight":"animal health / veterinary pharma","consensusComparison":"no consensus figures cited, limiting surprise quantification","householdBrandBoost":"leading global animal-health brand in Europe","retailFavoriteBoost":"none (US retail audience limited, foreign listing)"}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"bullish","material_impact_score":4,"narrative":"Virbac delivered H1 2026 organic revenue growth of +7.4% with an adjusted EBIT margin of 18.8%, up 0.5ppt versus H1 2025.\n\nGrowth was broad-based: companion animal rose +10.0% and farm animal +6.7% at CERS, with Supercharge platforms up around +12% and a ~+5.4% volume/mix contribution plus ~+2% price.\n\nConsolidated net income increased +5.9% to €87.1 million, while net debt rose to €196 million from €173 million at year-end 2025, attributed mainly to normal working-capital seasonality.\n\nManagement confirmed 2026 guidance at the upper end of the initial range, targeting 5.5%-7.5% revenue growth at CERS and an adjusted recurring operating income margin of around 17%.","key_figures":{"guidance":"2026 revenue growth at the upper end of the 5.5%-7.5% CERS range; adjusted recurring operating income margin around 17% at CERS","revenueYoy":"+7.4% organic growth at CERS","customDimensions":{"net_debt":"€196 million (June 2026)","net_income":"€87.1 million","price_effect":"~+2%","net_debt_dec_2025":"€173 million","net_income_growth":"+5.9%","volume_mix_effect":"~+5.4%","farm_animal_growth":"+6.7% at CERS","adjusted_ebit_margin":"18.8%","companion_animal_growth":"+10.0% at CERS","operating_margin_change":"+0.5ppt vs H1 2025","supercharge_platform_growth":"+12% at CERS (excl. Thyronorm)"}},"named_entities":{"people":[{"name":"Paul Martingell","role":"Chief Executive Officer"}],"products":["Supercharge platforms","Thyronorm"],"companies":[{"name":"Virbac","ticker":"VIRB","relationship":"filer"}],"dollarAmounts":[{"amount":"€87.1 million","context":"H1 2026 consolidated net income"},{"amount":"€196 million","context":"net debt as of June 2026"},{"amount":"€173m","context":"net debt as of December 2025"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-17T16:34:10.664Z","global_importance":42,"audience_relevance":35,"importance_components":{"tickerTier":"large European animal-health issuer (Euronext Paris)","eventGravity":"H1 earnings with growth and margin expansion plus upper-end guidance confirmation","sectorWeight":"animal health / veterinary pharma","consensusComparison":"no consensus figures cited, limiting surprise quantification","householdBrandBoost":"leading global animal-health brand in Europe","retailFavoriteBoost":"none (US retail audience limited, foreign listing)"}},"durationMs":28448,"modelName":"glm-5.3-flash"}}